1. Home
  2. HFBL vs GANX Comparison

HFBL vs GANX Comparison

Compare HFBL & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HFBL
  • GANX
  • Stock Information
  • Founded
  • HFBL 1924
  • GANX 2017
  • Country
  • HFBL United States
  • GANX United States
  • Employees
  • HFBL N/A
  • GANX N/A
  • Industry
  • HFBL Savings Institutions
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HFBL Finance
  • GANX Health Care
  • Exchange
  • HFBL Nasdaq
  • GANX Nasdaq
  • Market Cap
  • HFBL 41.7M
  • GANX 45.8M
  • IPO Year
  • HFBL N/A
  • GANX 2021
  • Fundamental
  • Price
  • HFBL $13.35
  • GANX $1.85
  • Analyst Decision
  • HFBL
  • GANX Strong Buy
  • Analyst Count
  • HFBL 0
  • GANX 6
  • Target Price
  • HFBL N/A
  • GANX $8.33
  • AVG Volume (30 Days)
  • HFBL 3.6K
  • GANX 265.8K
  • Earning Date
  • HFBL 04-29-2025
  • GANX 05-13-2025
  • Dividend Yield
  • HFBL 3.90%
  • GANX N/A
  • EPS Growth
  • HFBL N/A
  • GANX N/A
  • EPS
  • HFBL 1.09
  • GANX N/A
  • Revenue
  • HFBL $19,713,000.00
  • GANX N/A
  • Revenue This Year
  • HFBL N/A
  • GANX N/A
  • Revenue Next Year
  • HFBL N/A
  • GANX N/A
  • P/E Ratio
  • HFBL $12.46
  • GANX N/A
  • Revenue Growth
  • HFBL N/A
  • GANX N/A
  • 52 Week Low
  • HFBL $10.60
  • GANX $0.89
  • 52 Week High
  • HFBL $14.08
  • GANX $3.65
  • Technical
  • Relative Strength Index (RSI)
  • HFBL 55.00
  • GANX 50.94
  • Support Level
  • HFBL $13.10
  • GANX $1.67
  • Resistance Level
  • HFBL $13.57
  • GANX $1.82
  • Average True Range (ATR)
  • HFBL 0.10
  • GANX 0.17
  • MACD
  • HFBL 0.02
  • GANX 0.03
  • Stochastic Oscillator
  • HFBL 48.16
  • GANX 84.34

About HFBL Home Federal Bancorp Inc. of Louisiana

Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: